To the best of our knowledge, our study is the first systematic review and meta-analysis examining the impact of PD-1/PD-L1 inhibitors and standard chemotherapy on QoL in patients with NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.